Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2023 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
August 31, 2023 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 2023 Wells Fargo Healthcare Conference on Thursday,...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 14, 2023 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on August 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Reports Second Quarter 2023 Financial Results
August 03, 2023 16:01 ET
|
Travere Therapeutics, Inc.
• Received 417 new patient start forms for FILSPARI™(sparsentan) in the second quarter 2023, reflecting continued strong demand from nephrologists and patients with IgA nephropathy (IgAN) • ...
Travere Therapeutics to Report Second Quarter 2023 Financial Results
July 20, 2023 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2023 financial results on Thursday, August 3, 2023, after the...
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
July 17, 2023 08:00 ET
|
Travere Therapeutics, Inc.
• Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal® • Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2023 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2023, the Compensation Committee of its Board of Directors granted inducement...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2023 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present at Upcoming Investor Conferences
June 01, 2023 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: William...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 11, 2023 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2023, the Compensation Committee of its Board of Directors granted...